These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30555037)

  • 41. [Treatment of uncomplicated lower urinary tract infections].
    Horcajada JP; García-Palomo D; Fariñas MC
    Enferm Infecc Microbiol Clin; 2005 Dec; 23 Suppl 4():22-7. PubMed ID: 16854355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.
    Rice LB
    Mayo Clin Proc; 2012 Feb; 87(2):198-208. PubMed ID: 22305032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antimicrobial drug resistant pathogens in nosocomial urinary tract infections--selected aspects].
    Kamińska W; Dzierzanowska D
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():25-32. PubMed ID: 15669199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?
    Cooper TW; Pass SE; Brouse SD; Hall RG
    Ann Pharmacother; 2011 Feb; 45(2):229-40. PubMed ID: 21304038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit?
    Rahme C; Butterfield JM; Nicasio AM; Lodise TP
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):239-59. PubMed ID: 25308565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preserving the Dwindling β-lactams-Based Empiric Therapy Options for Gram-Negative Infections in Challenging Resistance Scenario: Lessons Learned and Way Forward.
    Palwe S; Khobragade K; Kharat AS
    Microb Drug Resist; 2020 Jun; 26(6):637-651. PubMed ID: 31851576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
    Harada S; Ishii Y; Yamaguchi K
    Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria.
    Pallett A; Hand K
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 3():iii25-33. PubMed ID: 20876625
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?
    Harris PN; Ferguson JK
    Int J Antimicrob Agents; 2012 Oct; 40(4):297-305. PubMed ID: 22824371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.
    Carson C; Naber KG
    Drugs; 2004; 64(12):1359-73. PubMed ID: 15200349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [News of antibiotic resistance among Gram-negative bacilli in Algeria].
    Baba Ahmed-Kazi Tani Z; Arlet G
    Pathol Biol (Paris); 2014 Jun; 62(3):169-78. PubMed ID: 24819127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives.
    Garcia-Bustos V; Cabañero-Navalón MD; Salavert Lletí M
    Rev Esp Quimioter; 2022 Sep; 35 Suppl 2(Suppl 2):1-15. PubMed ID: 36193979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
    D'Angelo RG; Johnson JK; Bork JT; Heil EL
    Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Resistance in gram-negative bacteria: enterobacteriaceae.
    Paterson DL
    Am J Med; 2006 Jun; 119(6 Suppl 1):S20-8; discussion S62-70. PubMed ID: 16735147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Global dissemination of beta-lactamases mediating resistance to cephalosporins and carbapenems.
    Gootz TD
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):317-27. PubMed ID: 15482196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Detection of resistance phenotypes in gram-negative bacteria].
    Navarro F; Calvo J; Cantón R; Fernández-Cuenca F; Mirelis B
    Enferm Infecc Microbiol Clin; 2011; 29(7):524-34. PubMed ID: 21696863
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beta-lactam antibiotics: newer formulations and newer agents.
    Martin SI; Kaye KM
    Infect Dis Clin North Am; 2004 Sep; 18(3):603-19, ix. PubMed ID: 15308278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.